1.
Open Forum Infect Dis
; 11(1): ofad633, 2024 Jan.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38288349
RESUMEN
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel therapeutic option for hematologic malignancies. Human immunodeficiency virus (HIV) nucleic acid amplification tests (NAATs) amplifying 5' long terminal repeat and gag genes cross-react with lentiviral vector-based CAR T-cell products. Cross-reactivity between CAR T-cell products and HIV NAATs may lead to false-positive test results.